Spectracure AB (publ.) is a business-to-business service provider based in Lund, specializing in the development of innovative cancer treatment solutions. The company focuses on curative therapies that aim to minimize side effects, particularly in the treatment of solid tumors. A significant aspect of their work is dedicated to improving outcomes for patients with prostate cancer, addressing the specific challenges associated with this condition.
The leadership team at Spectracure includes CEO Johannes Swartling and Chairman Jörgen Wennberg, who guide the company's strategic direction. The organization is actively engaged in research and development, working on advanced medical technologies that seek to enhance the quality of life for patients undergoing cancer treatment. Through its commitment to effective therapies, Spectracure aims to contribute positively to the field of oncology and improve patient care.